Cannabinoids, Clinical Trials and Workshop

TGA – Australia: Independent Expert Panel on MDMA and psilocybin – Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions

Cannabis Law Report

OCTOBER 5, 2021

The review excludes pre-clinical trials (i.e. Professor Mark Connor is a molecular pharmacologist with expertise in analgesics and psychoactive drugs, particularly cannabinoids and opioids, with extensive research experience in the USA, UK, and Australia. experimental pharmacology studies in test tube or animal models).

Treatment

Treatment Conditions Medicine Clinical Trials

Breaking the Stigma: Shifting Attitudes Toward Medical Marijuana Nationwide

MMJ Recs

DECEMBER 22, 2023

One of the key drivers of this shift is the increasing body of scientific research highlighting the medical properties of cannabinoids, the active compounds in marijuana. Over the past decades, numerous studies have investigated the medicinal properties of cannabinoids, the active compounds in marijuana.

Marijuana

Marijuana Chronic Pain Advocacy Research and Development

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. in/ingmargorman/ [link]. in/joe-moore-90a488141/ [link].

Research and Development

Research and Development Medicine Treatment Pharmaceutical

Medical Cannabis Brief

TGA – Australia: Independent Expert Panel on MDMA and psilocybin – Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions

Breaking the Stigma: Shifting Attitudes Toward Medical Marijuana Nationwide

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Stay Connected